Page 151 - CW E-Magazine (10-12-2024)

Pharmaceuticals

EXPO NEWS
CPHI showcases Indian pharma’s capabilities

to global audience

The 17th edition of CPHI & PMEC
India, organised by Informa Markets
from November 26-28 at the India Expo
Centre, Greater Noida, showcased the
robust potential of India’s pharmaceutical
market, which is projected to grow to
$130-bn by 2030 and $450-bn by 2047,
and the industry’s vital role in shaping
global healthcare.

While CPHI India featured a wide
array of exhibitors, including suppliers
of Active Pharmaceutical Ingredients
(APIs), excipients, and drug formula-
tions, PMEC India highlighted inno-
vations in pharmaceutical equipment, highlight India’s dual strengths in will further strengthen the industry’s
including packaging and processing affordability and effi cacy, reaffi rming role, paving the way for dominance in
equipment, process automation, etc. its role as the ‘pharmacy of the world,” biologics and biosimilars,” Mr. Namit
Together, the two events brought to- said Mr. AVPS Chakravarthy, Global Joshi, Vice Chairman, Pharmexil,
gether over 2,000 exhibitors and 50,000 Ambassador, World Packaging Organi- said.
visitors from more than 150 countries, sation (WPO), in a press release issued
including the USA, UAE, South Korea, by the organisers. According to Mr. Yogesh Mudras,
Japan, and UK. Managing Director, Informa Markets
According to Dr. Veeramani, Chairman, in India, India’s leadership in the sector
The CPHI lineup of exhibitors in- Pharmexcil, the Indian pharma- stems from key advantages such as a low
cluded leading names like Dr. Reddy’s ceutical industry stands as a global manufacturing cost (30-35% lower than
Laboratories Ltd., Biocon Ltd., Glenmark leader, exporting to over 200 countries in the US and Europe), cost-effi cient
Lifesciences Ltd., Morepen Laboratories and providing comprehensive solutions R&D (at 87% less than developed mar-
Ltd., Hetero Labs Limited, Lupin Ltd., across APIs, fi nished dosages, clinical kets), and an abundant pool of skilled
Signet Excipients Pvt. Ltd., Apitoria research, and pharmacovigilance. “In- labor. “These strengths position India as
Pharma Pvt. Ltd., Capsugel Healthcare novations in biologics, specialty gene- a formidable player in shaping the future
Pvt. Ltd., Supriya Lifescience Ltd., SMS rics, and the impact of policies like of global healthcare,” he noted.
Pharmaceuticals Ltd., MSN Laboratories the US Biosecure Act underline the
Pvt. Ltd., Tirupati Lifesciences Pvt. Ltd., industry’s potential to redefi ne health- Mr. Adam Anderson, Executive
and Merck Life Science Pvt. Ltd., among care solutions worldwide.” Vice President – Pharma, Informa Markets
others. B.V, stated that by 2027, biopharma is
Mr. K. Raja Bhanu, Director General, projected to account for 35% of the
Strong growth potential Pharmexcil, noted that exports is a global market. “This growth extends
“The Indian pharmaceutical in- key focus area for the industry, contri- across the entire supply chain, includ-
dustry is demonstrating its innovative buting $27.85-bn to the current market ing contract manufacturing and pack-
potential through advancements like size of $55-bn. “Projections indicate aging, providing India with tremendous
Carticel therapy for cancer treatment exports will soar to $130-bn by 2030 opportunities,” he said.
and Nafi thromycin, a groundbreaking and $450-bn billion by 2047,” he added.
macrolide antibiotic tackling drug- Excellence in Pharma
resistant pathogens. These innovations “Integrating IT with pharmaceuticals Day 1 of the event showcased the

Chemical Weekly December 10, 2024 151

Contents Index to Advertisers Index to Products Advertised